Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TACR2 | P21452 | 1/20 | 0.41 |
| ▸ | MAG | P20916 | 1/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7774709 | 0.89 | MAPK1 (0.50) | HRASMAPK1L3MBTL1LGALS8TACR2 | |
| SCHEMBL31134199 | 0.88 | MAPK1 (0.58) | HRASMAPK1LGALS8POLBMAG | |
| SCHEMBL8822997 | 0.88 | MAPK1 (0.58) | HRASMAPK1LGALS8POLBMAG | |
| SCHEMBL13491610 | 0.87 | MAPK1 (0.48) | HRASMAPK1L3MBTL1LGALS8POLB | |
| SCHEMBL13296098 | 0.85 | TP53 (0.55) | TACR2LMNAKMT2A | |
| SCHEMBL1149278 | 0.83 | HRAS (0.49) | HRASLGALS8POLBMAGLGALS3 | |
| SCHEMBL22204678 | 0.82 | MAG (0.55) | HRASMAPK1L3MBTL1LGALS8POLB | |
| SCHEMBL5841546 | 0.82 | MAG (0.55) | HRASMAPK1L3MBTL1LGALS8POLB | |
| SCHEMBL5841006 | 0.82 | MAG (0.55) | HRASMAPK1L3MBTL1LGALS8POLB | |
| SCHEMBL5841001 | 0.82 | MAG (0.55) | HRASMAPK1L3MBTL1LGALS8POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190439-B1 | OSELTAMIVIR PHOSPHONATE DERIVATIVES WITH ANTI-INFLUENZA ACTIVITY AND SYNTHESIS THEREOF | ACADEMIA SINICA (TW) | 2016-03-09 | — | — | EP | disclosed |
| US-7888337-B2 | Synthesis of oseltamivir containing phosphonate congeners with anti-influenza activity | ACADEMIA SINICA (TW) | 2011-02-15 | — | — | US | disclosed |
| EP-2190439-A2 | SYNTHESIS OF OSELTAMIVIR CONTAINING PHOSPHONATE CONGENERS WITH ANTI-INFLUENZA ACTIVITY | Academia Sinica (TW) | 2010-06-02 | — | — | EP | disclosed |
| US-20100113397-A1 | SYNTHESIS OF OSELTAMIVIR CONTAINING PHOSPHONATE CONGENERS WITH ANTI-INFLUENZA ACTIVITY | ACADEMIA SINICA (TW) | 2010-05-06 | — | — | US | disclosed |
| WO-2009029888-A2 | SYNTHESIS OF OSELTAMIVIR CONTAINING PHOSPHONATE CONGENERS WITH ANTI-INFLUENZA ACTIVITY | WONG CHI-HUEY (US) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113397-A1 | SYNTHESIS OF OSELTAMIVIR CONTAINING PHOSPHONATE CONGENERS WITH ANTI-INFLUENZA ACTIVITY | TALDO1, DUSP4, PNP | HRAS 1168/4885MAPK1 591/4885L3MBTL1 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.